Tokushima University / Educator and Researcher Directory --- Miyazaki, Katsuki

Personal Web Page

https://orcid.org/0000-0003-0065-5296 (ORCID)

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mayuko Shimizu, Koichi Tsuneyama and Mitsuo Shimada : Inhibitory effect of non-alcoholic steatohepatitis on colon cancer liver metastasis., EJSO - European Journal of Surgical Oncology, Vol.49, No.2, 410-415, 2023. (Summary) The WD-fed NASH mouse model showed an inhibitory effect on CLM. Suppressed interleukin-6/signal transducer and activator of transcription 3 signaling and serum amyloid A/matrix metalloproteinase 9 expression may affect this phenomenon. (Keyword) Male / Mice / Animals / Non-alcoholic Fatty Liver Disease / Mice, Inbred C57BL / Liver / Liver Neoplasms / Disease Models, Animal / Colonic Neoplasms / RNA, Messenger (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ejso.2022.11.002 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36371329 ● Search Scopus @ Elsevier (PMID): 36371329 ● Search Scopus @ Elsevier (DOI): 10.1016/j.ejso.2022.11.002 (DOI: 10.1016/j.ejso.2022.11.002, PubMed: 36371329)
2.	Katsuki Miyazaki, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Tetsuya Ikemoto, Satoru Imura, Haun Hu, Hisayoshi Morioka, Koichi Tsuneyama and Mitsuo Shimada : Stromal tumor-infiltrating lymphocytes level as a prognostic factor for resected intrahepatic cholangiocarcinoma and its prediction by apparent diffusion coefficient., International Journal of Clinical Oncology, Vol.26, No.12, 2265-2274, 2021. (Summary) Tumor-infiltrating lymphocytes (TILs) are a prognostic factor or an indicator of chemotherapy response for various malignancies. The aim of this study was to investigate the prognostic impact of TILs in resected intrahepatic cholangiocarcinoma (IHCC). We also investigated the usefulness of the apparent diffusion coefficient (ADC) in diffusion-weighted magnetic resonance imaging (DW-MRI) to predict TILs. We enrolled 23 patients with IHCC who underwent initial hepatic resection in Tokushima University Hospital from 2006 to 2017. We evaluated stromal TILs in the tumor marginal area and central area in surgical specimens. Patients were divided into low vs high stromal TILs groups. We analyzed the patients' clinicopathological factors, including prognosis, according to the degree of stromal TILs. We also analyzed the correlation between stromal TILs and the minimum ADC value. Stromal TILs in the marginal area reflected overall survival more accurately than that in the central area. Additionally, marginal low TILs was significantly associated with lymph node metastasis and portal vein invasion. Both overall- and disease-free survival rates in the marginal low TILs group were significantly worse than those in the marginal high TILs group (P < 0.05). In the multivariate analysis, marginal low TILs were an independent prognostic factor for both overall- and disease-free survival (P < 0.05), and marginal low TILs were significantly associated with lower minimum ADC values (P < 0.02). Stromal TILs, especially in the marginal area, might demonstrate prognostic impact in patients with IHCC. Moreover, the ADC values from MRI may predict TILs in IHCC tumor tissue. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Diffusion Magnetic Resonance Imaging / Humans / Lymphocytes, Tumor-Infiltrating / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-021-02026-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34596803 ● Search Scopus @ Elsevier (PMID): 34596803 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-021-02026-3 (DOI: 10.1007/s10147-021-02026-3, PubMed: 34596803)
3.	Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Masato Miyake, Yuji Morine, Seiichi Oyadomari and Mitsuo Shimada : Effective three-dimensional culture of hepatocyte-like cells generated from human adipose-derived mesenchymal stem cells., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.28, No.9, 705-715, 2021. (Summary) The aim of this study was to clarify the effectiveness of a new three-dimensional (3D) culture system for hepatocyte-like cells (HLCs) generated from human adipose-derived mesenchymal stem cells (ADSCs). Human ADSCs (2 × 10 ) with or without 0.1 mg/mL human recombinant peptide μ-piece per well were seeded in a 96-well U-bottom plate and then our three-step differentiation protocol was applied for 21 days. At each step, cell morphology and gene expression were investigated. Mature hepatocyte functions were evaluated after HLC differentiation. These parameters were compared between 2D- and 3D-cultured HLCs, and, DNA microarray analysis was also performed. Finally, HLCs were transplanted in to CCl induced acute liver failure model mice. Two-dimensional-cultured HLCs at day 21 did not have a spindle shape and had formed spheroids after day 6, which gradually increased in size for 3D-cultured HLCs. Definitive endoderm, hepatoblast, and hepatocyte genes showed significantly higher expression in the 3D culture group. Three-dimensional-cultured HLCs also had higher albumin expression, CYP3A4 activity, urea synthesis, and ammonium metabolism, and much higher expression of ion transporter, blood coagulation, and cell communication genes. HLC transplantation improved serum liver function, especially in T-Bil levels, and engrafted into immunodeficient mice with HLA class I positive staining. Our new 3D culture protocol is effective to improve hepatocyte functions. Our HLCs might be promising for clinical cell transplantation to treat metabolic disease. (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.1024 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34318615 ● Search Scopus @ Elsevier (PMID): 34318615 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.1024 (DOI: 10.1002/jhbp.1024, PubMed: 34318615)
4.	Shoko Yamashita, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Chie Takasu, Shinichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : A new pathological classification of intrahepatic cholangiocarcinoma according to protein expression of SSTR2 and Bcl2., World Journal of Surgical Oncology, Vol.19, No.1, 142, 2021. (Summary) This method could be used to classify IHCC into peripheral and perihilar type by embryological expression patterns of SSTR2 and Bcl2. (Keyword) Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Humans / Prognosis / Proto-Oncogene Proteins c-bcl-2 / Receptors, Somatostatin (Tokushima University Institutional Repository) ● Metadata: 116986 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02216-3 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33962620 ● Search Scopus @ Elsevier (PMID): 33962620 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02216-3 (Tokushima University Institutional Repository: 116986, DOI: 10.1186/s12957-021-02216-3, PubMed: 33962620)
5.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the fibrinogen-platelet ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 342-346, 2021. (Summary) Background : Several prognostic factors were reported in pancreatic cancer. The fibrinogen-platelet ratio (FPR) was reported as a prognostic factor of resectable gastric cancer. In this report, the FPR was evaluated in patients with resectable pancreatic cancer. Methods : Between 2004 and 2019, 163 patients with curative resection for pancreatic cancer were enrolled. Cases of non-curative resection were excluded. The FPR was calculated using the preoperative plasma fibrinogen and the platelet counts and the cut-off value was determined by receiver operating characteristic (ROC) curve analysis. The patients were divided into high and low FPR groups according to this cut-off value. Results : The cut-off value of FPR was 25.2. Among age, sex, body mass index (BMI), and surgical factors including surgery type, volume of blood loss and surgery time, there was no significant difference between the two groups. Patients in the low FPR group had significantly better overall survival (OS) and relapse-free survival (RFS) compared with the high FPR group (P < 0.05). On multivariate analysis, a high FPR, CA19-9 > 300 U /l, and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. Conclusions : The FPR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 342-346, August, 2021. (Keyword) Biomarkers, Tumor / Fibrinogen / Humans / Neoplasm Recurrence, Local / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116535 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.342 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759156 ● Search Scopus @ Elsevier (PMID): 34759156 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.342 (Tokushima University Institutional Repository: 116535, DOI: 10.2152/jmi.68.342, PubMed: 34759156)

Academic Paper (Unrefereed Paper):

1.	Katsuki Miyazaki, Caiming Xu, Mitsuo Shimada and Ajay Goel : Curcumin and Andrographis Exhibit Anti-Tumor Effects in Colorectal Cancer via Activation of Ferroptosis and Dual Suppression of Glutathione Peroxidase-4 and Ferroptosis Suppressor Protein-1., Pharmaceuticals, Vol.16, No.3, 383, 2023. (Summary) Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide. The limitations of current chemotherapeutic drugs in CRC include their toxicity, side effects, and exorbitant costs. To assess these unmet needs in CRC treatment, several naturally occurring compounds, including curcumin and andrographis, have gained increasing attention due to their multi-targeted functionality and safety vs. conventional drugs. In the current study, we revealed that a combination of curcumin and andrographis exhibited superior anti-tumor effects by inhibiting cell proliferation, invasion, colony formation, and inducing apoptosis. Genome-wide transcriptomic expression profiling analysis revealed that curcumin and andrographis activated the ferroptosis pathway. Moreover, we confirmed the gene and protein expression of glutathione peroxidase 4 (GPX-4) and ferroptosis suppressor protein 1 (FSP-1), the two major negative regulators of ferroptosis, were downregulated by this combined treatment. With this regimen, we also observed that intracellular accumulation of reactive oxygen species and lipid peroxides were induced in CRC cells. These cell line findings were validated in patient-derived organoids. In conclusion, our study revealed that combined treatment with curcumin and andrographis exhibited anti-tumorigenic effects in CRC cells through activation of ferroptosis and by dual suppression of GPX-4 and FSP-1, which have significant potential implications for the adjunctive treatment of CRC patients. (Tokushima University Institutional Repository) ● Metadata: 119401 (Link to Publication Site) ● Publication site (DOI): 10.3390/ph16030383 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36986483 ● Search Scopus @ Elsevier (PMID): 36986483 ● Search Scopus @ Elsevier (DOI): 10.3390/ph16030383 (Tokushima University Institutional Repository: 119401, DOI: 10.3390/ph16030383, PubMed: 36986483)
2.	Katsuki Miyazaki, Yuji Morine, Caiming Xu, Chiharu Nakasu, Yuuma Wada, Hiroki Teraoku, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Mitsuo Shimada and Ajay Goel : Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma., Cells, Vol.12, No.4, 612, 2023. (Summary) Lenvatinib is a multi-kinase inhibitor approved as a first-line treatment for patients with unresectable advanced hepatocellular carcinoma (HCC). However, its response rate is unsatisfactory, primarily due to the acquisition of resistance, which limits its clinical significance for treating patients with HCC. Recent evidence suggests that epidermal growth factor receptor (EGFR) activation can trigger Lenvatinib-resistance; and is considered an important therapeutic target in HCC. Curcumin, one of the most studied naturally occurring botanicals with robust anti-cancer activity, is also reported to be a potent tyrosine kinase inhibitor. In this study, we hypothesized that the anti-EGFR potential of Curcumin might help overcome Lenvatinib resistance in HCC. We established two Lenvatinib-resistant cells and discovered that a combination of Curcumin and Lenvatinib exhibited a synergistic anti-tumor efficacy in the resistant HCC cell lines. In line with previous reports, Lenvatinib-resistant cell lines revealed significant activation of the EGFR, and genomewide transcriptomic profiling analysis identified that the PI3K-AKT pathway was associated with Lenvatinib resistance. The combination treatment with Curcumin and Lenvatinib dramatically suppressed gene and protein expression of the EGFR-PI3K-AKT pathway, suggesting Curcumin overcomes Lenvatinib resistance via inhibition of EGFR. We further validated these findings in tumor spheroids derived from resistant cell lines. In conclusion, we, for the first time, report that Curcumin reverses Lenvatinib resistance in HCC, and that their combination has clinical application potential for adjunctive treatment in HCC. (Keyword) Humans / Carcinoma, Hepatocellular / Curcumin / Liver Neoplasms / Proto-Oncogene Proteins c-akt / Phosphatidylinositol 3-Kinases / Cell Line, Tumor / Signal Transduction / Protein Kinase Inhibitors / ErbB Receptors (Tokushima University Institutional Repository) ● Metadata: 118580 (Link to Publication Site) ● Publication site (DOI): 10.3390/cells12040612 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36831279 ● Search Scopus @ Elsevier (PMID): 36831279 ● Search Scopus @ Elsevier (DOI): 10.3390/cells12040612 (Tokushima University Institutional Repository: 118580, DOI: 10.3390/cells12040612, PubMed: 36831279)
3.	Katsuki Miyazaki, Yuuma Wada, Keisuke Okuno, Tatsuro Murano, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroaki Ikematsu, Yusuke Kinugasa, Mitsuo Shimada and Ajay Goel : An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer., Molecular Cancer, Vol.22, No.1, 2, 2023. (Summary) According to current guidelines, more than 70% of patients with invasive submucosal colorectal cancer (T1 CRC) undergo a radical operation with lymph node dissection, even though only ~ 10% have lymph node metastasis (LNM). Hence, there is imperative to develop biomarkers that can help robustly identify LNM-positive patients to prevent such overtreatments. Given the emerging interest in exosomal cargo as a source for biomarker development in cancer, we examined the potential of exosomal miRNAs as LNM prediction biomarkers in T1 CRC. We analyzed 200 patients with high-risk T1 CRC from two independent cohorts, including a training (n = 58) and a validation cohort (n = 142). Cell-free and exosomal RNAs from pre-operative serum were extracted, followed by quantitative reverse-transcription polymerase chain reactions for a panel of miRNAs. A panel of four miRNAs (miR-181b, miR-193b, miR-195, and miR-411) exhibited robust ability for detecting LNM in the exosomal vs. cell-free component. We subsequently established a cell-free and exosomal combination signature, successfully validated in two independent clinical cohorts (AUC, 0.84; 95% CI 0.70-0.98). Finally, we developed a risk-stratification model by including key pathological features, which reduced the false positive rates for LNM by 76% without missing any true LNM-positive patients. Our novel exosomal miRNA-based liquid biopsy signature robustly identifies T1 CRC patients at risk of LNM in a preoperative setting. This could be clinically transformative in reducing the significant overtreatment burden of this malignancy. (Keyword) Humans / Lymphatic Metastasis / Exosomes / Colorectal Neoplasms / Biomarkers, Tumor / MicroRNAs / Liquid Biopsy (Tokushima University Institutional Repository) ● Metadata: 118926 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12943-022-01685-8 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36609320 ● Search Scopus @ Elsevier (PMID): 36609320 ● Search Scopus @ Elsevier (DOI): 10.1186/s12943-022-01685-8 (Tokushima University Institutional Repository: 118926, DOI: 10.1186/s12943-022-01685-8, PubMed: 36609320)
4.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Yuhei Waki, Shohei Okikawa, Katsuki Miyazaki, Chiharu Nakasu, Takayuki Noma, Akira Takahashi and Mitsuo Shimada : Impact of pancreatic resection in patients with liver cirrhosis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 189-194, 2023. (Summary) Several reports have shown a high mortality rate in patients with liver cirrhosis (LC) who undergo pancreaticoduodenectomy, however, there are few reports on its long-term prognosis. Twelve patients with LC who had undergone pancreatic resection were enrolled. To compare clinicopathological variables, 159 non-LC patients who had undergone resection for pancreatic cancer were enrolled. Pancreaticoduodenectomy (PD) was performed in 5 LC patients and distal pancreatectomy (DP) was performed in 7 LC patients. Patients in the LC group had more co-morbidities, lower platelet counts and higher Fib4 index than the non-LC group. The postoperative complication rate was higher in the LC group (83.3% vs 47.8%). While the postoperative hospital stay and 30-day mortality rate were not different, the 90-day mortality rate was higher in the LC group (25.0% vs 2.5% ; p<0.01). Comparison by operative procedure showed no significant differences of postoperative outcomes in DP cases. However, in PD cases, postoperative complications were more frequent (100% vs 42.3%) and 90-day mortality was higher (40.0% vs 2.9% ; p<0.01) in the LC group. PD resulted in higher postoperative morbidity and mortality rates in patients with LC compared with non-LC patients. DP could be tolerated in the LC patients. J. Med. Invest. 70 : 189-194, February, 2023. (Keyword) Humans / Pancreatectomy / Treatment Outcome / Retrospective Studies / Pancreaticoduodenectomy / Pancreatic Neoplasms / Postoperative Complications / Liver Cirrhosis (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.189 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164719 ● Search Scopus @ Elsevier (PMID): 37164719 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.189 (DOI: 10.2152/jmi.70.189, PubMed: 37164719)
5.	Hiroki Teraoku, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Short- and long-term outcomes of pancreatectomy in patients with hemodialysis., The Journal of Medical Investigation : JMI, Vol.70, No.1.2, 105-109, 2023. (Summary) Several reports have shown the high mortality rate of pancreatic resection in patients with hemodialysis (HD), however, its long-term outcome remains unclear. In this study, we examined cases of pancreatic resection in patients with HD and conducted a literature review. Four patients with HD who underwent pancreatic resection from 2004 to 2019 were enrolled. To compare the clinicopathological variables of HD and non-HD patients, 161 non-HD patients who had undergone surgical resection for pancreatic cancer were enrolled. Among four cases of pancreatic resection with HD, three cases were malignant diseases. All patients with HD had some co-morbidities (100% in HD group, 45.3% in the non-HD group) and postoperative complications (100% in the HD group, vs 46.6% in the non-HD group). Although one patient had severe postoperative complications and length of postoperative hospital stay was longer, the 30- and 90-day mortality rates were both 0% in patients with HD. However, three cases in the HD group (75%) died approximately 6 months after surgery, including one cancer-related death. Pancreatic surgery in patients with HD should be carefully indicated, especially pancreaticoduodenectomy or total pancreatectomy, because of the poor prognosis induced by non-cancer-related causes of death. J. Med. Invest. 70 : 105-109, February, 2023. (Keyword) Humans / Pancreatectomy / Pancreatic Neoplasms / Pancreaticoduodenectomy / Postoperative Complications / Retrospective Studies (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.70.105 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37164704 ● Search Scopus @ Elsevier (PMID): 37164704 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.70.105 (DOI: 10.2152/jmi.70.105, PubMed: 37164704)
6.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yuji Morine and Mitsuo Shimada : Newly Generated 3D Schwann-Like Cell Spheroids From Human Adipose-Derived Stem Cells Using a Modified Protocol., Cell Transplantation, Vol.31, 9636897221093312, 2022. (Summary) Peripheral nerve injury (PNI) is a relatively frequent type of trauma that results in the suffering of many patients worldwide every year. Schwann cells (SCs) are expected to be applied in cell therapy because of their ability to promote peripheral nerve regeneration. However, the lack of clinically renewable sources of SCs hinders the application of SC-based therapies. Adipose-derived stem cells (ADSCs) have generated great interest in recent years because of their multipotency and ease of harvest, and they have already been verified to differentiate into Schwann-like cells (SLCs) in vitro. However, the efficiency of differentiation and the functions of SLCs remain unsatisfactory. We newly generated three-dimensional (3D) SLC spheroids from ADSCs using a modified protocol with human recombinant peptide (RCP) petaloid -piece. Morphological analysis, gene expression analysis by qRT-PCR, ELISA measurement of the secretion capabilities of neurotrophic factors, and neurite formation assay were performed to evaluate the functions of these 3D SLCs in vitro. Motor function recovery was measured in a sciatic nerve injury mouse model to analyze the nerve regeneration-promoting effect of 3D SLCs in vivo. The differentiation efficiency and the secretion of neurotrophic factors were enhanced in 3D SLCs compared with conventional SLCs. 3D SLCs could more effectively promote neurite growth and longer neurite extension in a neuron-like SH-SY5Y model. Additionally, 3D SLCs had a better therapeutic effect on nerve regeneration after transplantation into the sciatic nerve injury mouse model. These findings demonstrated that the potential of ADSC-derived SLCs to promote nerve regeneration could be significantly increased using our modified differentiation protocol and by assembling cells into a 3D sphere conformation. Therefore, these cells have great potential and can be used in the clinical treatment of PNI. (Keyword) Adipocytes / Adipose Tissue / Animals / Humans / Mice / Nerve Growth Factors / Peripheral Nerve Injuries / Schwann Cells / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 117435 (Link to Publication Site) ● Publication site (DOI): 10.1177/09636897221093312 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35469470 ● Search Scopus @ Elsevier (PMID): 35469470 ● Search Scopus @ Elsevier (DOI): 10.1177/09636897221093312 (Tokushima University Institutional Repository: 117435, DOI: 10.1177/09636897221093312, PubMed: 35469470)
7.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Chie Takasu, Katsuki Miyazaki and Mitsuo Shimada : Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant hepatocellular carcinoma cells., PLoS ONE, Vol.16, No.9, e0256755, 2021. (Summary) As a multiple tyrosine kinase inhibitor, sorafenib is widely used to treat hepatocellular carcinoma (HCC), but patients frequently face resistance problems. Because the mechanism controlling sorafenib-resistance is not well understood, this study focused on the connection between tumor characteristics and the Nrf2 signaling pathway in a sorafenib-resistant HCC cell line. A sorafenib-resistant HCC cell line (Huh7) was developed by increasing the dose of sorafenib in the culture medium until the target concentration was reached. Cell morphology, migration/invasion rates, and expression of stemness-related and ATP-binding cassette (ABC) transporter genes were compared between sorafenib-resistant Huh7 cells and parental Huh7 cells. Next, a small interfering RNA was used to knock down Nrf2 expression in sorafenib-resistant Huh7 cells, after which cell viability, stemness, migration, and ABC transporter gene expression were examined again. Proliferation, migration, and invasion rates of sorafenib-resistant Huh7 cells were significantly increased relative to the parental cells with or without sorafenib added to the medium. The expression levels of stemness markers and ABC transporter genes were up-regulated in sorafenib-resistant cells. After Nrf2 was knocked down in sorafenib-resistant cells, cell migration and invasion rates were reduced, and expression levels of stemness markers and ABC transporter genes were reduced. Nrf2 signaling promotes cancer stemness, migration, and expression of ABC transporter genes in sorafenib-resistant HCC cells. (Keyword) ATP-Binding Cassette Transporters / Antineoplastic Agents / Carcinoma, Hepatocellular / Cell Line, Tumor / Cell Movement / Cell Proliferation / Cell Survival / Drug Resistance, Neoplasm / Gene Expression / Gene Expression Regulation, Neoplastic / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-E2-Related Factor 2 / Protein Kinase Inhibitors / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 117382 (Link to Publication Site) ● Publication site (DOI): 10.1371/journal.pone.0256755 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34473785 ● Search Scopus @ Elsevier (PMID): 34473785 ● Search Scopus @ Elsevier (DOI): 10.1371/journal.pone.0256755 (Tokushima University Institutional Repository: 117382, DOI: 10.1371/journal.pone.0256755, PubMed: 34473785)
8.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Tetsuya Ikemoto and Mitsuo Shimada : Frailty Can Predict Prognosis After Hepatectomy in Patients With Colorectal Liver Metastasis., Anticancer Research, Vol.41, No.9, 4637-4644, 2021. (Summary) The aim of this study was to investigate frailty as a prognostic factor in patients with colorectal liver metastasis undergoing hepatectomy. Eighty-seven patients who underwent hepatectomy at our institution were enrolled. Frailty was defined as a score of ·4 on a clinical frailty scale. Patients were divided into frailty (n=29) and non-frailty (n=58) groups. Overall and cancer-specific survival rates were significantly worse in the frailty group compared with the non-frailty group, and multivariate analysis revealed frailty as an independent prognostic factor. Disease-free survival tended to be worse in the frailty group. Fifty-eight patients relapsed after the first hepatectomy. Twenty-one of 58 recurrent patients were allocated to the frailty group. After recurrence, chemotherapy was significantly more frequently performed in the non-frailty group compared with the frailty group. Frailty can predict the prognosis of patients with colorectal liver metastasis undergoing hepatectomy. (Keyword) Adult / Aged / Aged, 80 and over / Colorectal Neoplasms / Drug Therapy / Female / Frailty / Hepatectomy / Humans / Liver Neoplasms / Male / Middle Aged / Multivariate Analysis / Neoplasm Recurrence, Local / Prognosis / Retrospective Studies / Survival Analysis / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.21873/anticanres.15277 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34475092 ● Search Scopus @ Elsevier (PMID): 34475092 ● Search Scopus @ Elsevier (DOI): 10.21873/anticanres.15277 (DOI: 10.21873/anticanres.15277, PubMed: 34475092)
9.	Luping Gao, Yuji Morine, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shouhei Okikawa, Chie Takasu and Mitsuo Shimada : The BAFF/NF B axis is crucial to interactions between sorafenib-resistant HCC cells and cancer-associated fibroblasts., Cancer Science, Vol.112, No.9, 3545-3554, 2021. (Summary) The tumor microenvironment affects malignancy in hepatocellular carcinoma (HCC) cells, and cancer-associated fibroblasts (CAFs) play an important role in the microenvironment. As recent studies indicated a difference between CAFs isolated from chemoresistant and non-resistant cancer tissues, therefore we investigated the intracellular mechanism in resistant HCC co-cultured CAFs and interactions between these CAFs with cancer cells. We established a sorafenib-resistant (SR) Huh7 (human HCC) cell line, and characterized it with cytokine assays, then developed CAFs by co-culturing human hepatic stellate cells with resistant or parental Huh7 cells. The 2 types of CAFs were co-cultured with parental Huh7 cells, thereafter the cell viability of these Huh7 cells was checked under sorafenib treatment. The SR Huh7 (Huh7 ) cells expressed increased B-cell activating factor (BAFF), which promoted high expression of CAF-specific markers in Huh7 -co-cultured CAFs, showed activated BAFF, BAFF-R, and downstream of the NF B-Nrf2 pathway, and aggravated invasion, migration, and drug resistance in co-cultured Huh7 cells. When we knocked down BAFF expression in Huh7 cells, the previously increased malignancy and BAFF/NF B axis in Huh7 -co-cultured CAFs reversed, and enhanced chemoresistance in co-cultured Huh7 cells returned as well. In conclusion, the BAFF/NF B pathway was activated in CAFs co-cultured with cell-culture medium from resistant Huh7, which promoted chemoresistance, and increased the malignancy in co-cultured non-resistant Huh7 cells. This suggests that the BAFF/NF B axis in CAFs might be a potential therapeutic target in chemoresistance of HCC. (Keyword) Antineoplastic Agents / B-Cell Activating Factor / Cancer-Associated Fibroblasts / Carcinoma, Hepatocellular / Cell Communication / Cell Line, Tumor / Cell Movement / Cell Survival / Coculture Techniques / Drug Resistance, Neoplasm / Gene Knockdown Techniques / Humans / Liver Neoplasms / NF-kappa B / Signal Transduction / Sorafenib / Transfection (Tokushima University Institutional Repository) ● Metadata: 116388 (Link to Publication Site) ● Publication site (DOI): 10.1111/cas.15041 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34159680 ● Search Scopus @ Elsevier (PMID): 34159680 ● Search Scopus @ Elsevier (DOI): 10.1111/cas.15041 (Tokushima University Institutional Repository: 116388, DOI: 10.1111/cas.15041, PubMed: 34159680)
10.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : Preoperative lymphocyte/C-reactive protein ratio and its correlation with CD8 tumor-infiltrating lymphocytes as a predictor of prognosis after resection of intrahepatic cholangiocarcinoma., Surgery Today, Vol.51, No.12, 1985-1995, 2021. (Summary) To clarify whether the preoperative lymphocyte/C-reactive protein (CRP) ratio (LCR) is a prognostic factor for patients with intrahepatic cholangiocarcinoma (IHCC), and investigate its mechanism via tumor-infiltrating lymphocytes. The subjects of this retrospective study were 42 patients who had undergone hepatectomy for IHCC. We divided the patients into low LCR and high LCR groups (cutoff value: 8780) and analyzed their overall survival (OS) and disease-free survival (DFS) with respect to LCR and other clinicopathological factors. We also investigated the levels of stromal tumor-infiltrating lymphocytes (TILs) and CD8 TILs in surgical specimens, and the relationship between LCR and TILs. A low LCR was identified in 21 patients and was significantly correlated with older age, a high CRP-albumin ratio, and advanced disease stage, and was a prognostic factor for OS and DFS. Multivariate analysis revealed that a low LCR was an independent prognostic factor for worse OS (HR 10.40, P = 0.0077). Although the LCR and levels of stromal TILs were not significantly related, LCR and levels of CD8 TILs were significantly related (P = 0.0297). The preoperative LCR may predict the postsurgical prognosis of patients with IHCC and reflect the CD8 TILs. (Keyword) Bile Duct Neoplasms / Biomarkers, Tumor / C-Reactive Protein / CD8-Positive T-Lymphocytes / Cholangiocarcinoma / Female / Humans / Lymphocyte Count / Lymphocytes, Tumor-Infiltrating / Male / Predictive Value of Tests / Preoperative Period / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1007/s00595-021-02295-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34009433 ● Search Scopus @ Elsevier (PMID): 34009433 ● Search Scopus @ Elsevier (DOI): 10.1007/s00595-021-02295-5 (DOI: 10.1007/s00595-021-02295-5, PubMed: 34009433)
11.	Chie Takasu, Katsuki Miyazaki, Kouzou Yoshikawa, Masaaki Nishi, Takuya Tokunaga, Hideya Kashihara, Toshiaki Yoshimoto, Hirohisa Ogawa, Yuji Morine and Mitsuo Shimada : Effect of TU-100 on Peyer's patches in a bacterial translocation rat model., Annals of Gastroenterological Surgery, Vol.5, No.5, 683-691, 2021. (Summary) Daikenchuto (TU-100), a Japanese herbal medicine, is widely used for various gastrointestinal diseases. We have previously reported that TU-100 suppresses CPT-11-induced bacterial translocation (BT) by maintaining the diversity of the microbiome. In this study we show that TU-100 modulates the immune response during BT by inducing PD-1 expression in Peyer's patches. Eighteen male Wistar rats were divided into four groups: a control group; a control + TU-100 group, given TU-100 1000 mg/kg orally for 5 d; a BT group, given CPT-11 250 mg/kg intra-peritoneal for 2 d; and a TU-100 group, given TU-100 1000 mg/kg orally for 5 d with CPT-11 250 mg/kg intra-peritoneal on days 4 and 5. The size of Peyer's patch was significantly bigger in the BT group compared to the control group (9.0 104 m vs 29.4 104 m, < .05), but improved in the TU-100 group (15.4 104 m, < .005). TU-100 significantly induced PD-1 expression in Peyer's patch compared to the control group and the BT group (control vs BT vs TU-100 = 4.3 4.9 vs 5.1 10.3 vs 17.9 17.8). The CD4 cells were increased in the BT group ( < .05) compared to the control group but decreased in the TU-100 group. The Foxp3 cells were increased in the BT group compared to the control group ( < .05), and further increased in the TU-100 group compared to the BT group. CPT-11 significantly increased TLR4, NF- , TNF- mRNA expressions in the BT group. TU-100 cotreatment significantly reversed these mRNA expressions. TU-100 may have a protective effect against BT through PD-1 expression in Peyer's patch. (Tokushima University Institutional Repository) ● Metadata: 117275 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12460 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34585053 ● Search Scopus @ Elsevier (PMID): 34585053 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12460 (Tokushima University Institutional Repository: 117275, DOI: 10.1002/ags3.12460, PubMed: 34585053)
12.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Takuya Tokunaga and Masaaki Nishi : Significance of frailty in prognosis after surgery in patients with pancreatic ductal adenocarcinoma., World Journal of Surgical Oncology, Vol.19, No.1, 94, 2021. (Summary) Frailty is an important consideration for older patients undergoing surgery. We aimed to investigate whether frailty could be a prognostic factor in patients with pancreatic ductal adenocarcinoma who underwent pancreatic resection. One hundred and twenty patients who underwent pancreatic resection for pancreatic ductal adenocarcinoma were enrolled. Frailty was defined as a clinical frailty scale score ·4. Patients were divided into frailty (n = 29) and non-frailty (n=91) groups, and clinicopathological factors were compared between the two groups. The frailty group showed an older age, lower serum albumin concentration, lower prognostic nutritional index, larger tumor diameter, and higher rate of lymph node metastasis than the non-frailty group (p < 0.05). Neutrophil-lymphocyte ratio and modified Glasgow prognostic score tended to be higher in the frailty group. Cancer-specific and disease-free survival rates were significantly poor in the frailty group (p < 0.05). With a multivariate analysis, frailty was an independent prognostic factor of cancer-specific survival. Frailty can predict the prognosis of patients with pancreatic ductal adenocarcinoma who undergo pancreatic resection. (Keyword) Aged / Carcinoma, Pancreatic Ductal / Frailty / Humans / Pancreatectomy / Pancreatic Neoplasms / Prognosis (Tokushima University Institutional Repository) ● Metadata: 116675 (Link to Publication Site) ● Publication site (DOI): 10.1186/s12957-021-02205-6 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33781262 ● Search Scopus @ Elsevier (PMID): 33781262 ● Search Scopus @ Elsevier (DOI): 10.1186/s12957-021-02205-6 (Tokushima University Institutional Repository: 116675, DOI: 10.1186/s12957-021-02205-6, PubMed: 33781262)
13.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Masaaki Nishi, Takuya Tokunaga, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : The interaction between cancer associated fibroblasts and tumor associated macrophages via the osteopontin pathway in the tumor microenvironment of hepatocellular carcinoma., Oncotarget, Vol.12, No.4, 333-343, 2021. (Summary) Cancer-tumor associated macrophage (TAM)-cancer associated fibroblast (CAF) interactions are an important factor in the tumor microenvironment of hepatocellular carcinoma. Hepatic stellate cells (HSCs) were cultured with cancer cell-conditioned medium (Ca.-CM), TAM-CM and CAF-CM, and the expression of CAF markers were evaluated by RT-PCR. Whether HSCs cultured with Ca.-CM, TAM-CM and CAF-CM contributed to the enhanced malignancy of cancer cells was examined using proliferation, invasion and migration assays. Furthermore, the differences between these three types of CM were evaluated using cytokine arrays. HSCs cultured with Ca.-CM, TAM-CM and CAF-CM showed significantly increased mRNA expression of SMA, FAP and IL-6. All HSCs cultured with each CM exhibited significantly increased proliferation, invasion and migration of cancer cells. The osteopontin concentration was significantly higher in HSCs cultured with TAM-CM than the other CAF-CMs. Osteopontin inhibition significantly reduced osteopontin secretion from HSCs cultured with TAM-CM and suppressed the proliferation and invasion of cancer cells enhanced by HSCs cultured with TAM-CM. We observed enhanced osteopontin secretion from TAMs, and this increased osteopontin further promoted osteopontin secretion from HSCs cultured with TAM-CM, leading to increased malignancy. For the first time, we demonstrated the importance of cancer-TAM-CAF interactions via osteopontin in hepatocellular carcinoma. (Tokushima University Institutional Repository) ● Metadata: 116612 (Link to Publication Site) ● Publication site (DOI): 10.18632/oncotarget.27881 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33659044 ● Search Scopus @ Elsevier (PMID): 33659044 ● Search Scopus @ Elsevier (DOI): 10.18632/oncotarget.27881 (Tokushima University Institutional Repository: 116612, DOI: 10.18632/oncotarget.27881, PubMed: 33659044)
14.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of Frailty in Prognosis After Hepatectomy for Elderly Patients with Hepatocellular Carcinoma., Annals of Surgical Oncology, Vol.28, No.1, 439-446, 2021. (Summary) The concept of frailty becomes important for patients who undergo surgery in this recent aging society. The aim of this study is to investigate the frailty as a prognostic factor in elderly patients with hepatocellular carcinoma (HCC) who underwent hepatectomy. A total of 92 patients over 75 years old who underwent hepatectomy were enrolled in this study. Frailty was defined as clinical frailty scale (CFS) 4. Patients were divided into two groups, i.e., frailty group (n = 21) and no-frailty group (n = 71), and clinicopathological features were compared between them. The frailty group showed significant higher PIVKA-II level and larger tumor diameter (p < 0.05). CRP level and modified Glasgow prognostic score were significantly higher in the frailty group (p < 0.05). The frailty group showed higher rate of postoperative complications of Clavien-Dindo III (p = 0.06) and longer postoperative stay (p = 0.08). Cancer-specific, overall, and disease-free survival rates were significantly worse in the frailty group (p < 0.05). Frailty was detected as an independent prognostic factor on multivariate analysis of cancer-specific survival. Frailty can estimate the prognosis of HCC patients who underwent hepatectomy. (Keyword) Aged / Carcinoma, Hepatocellular / Frail Elderly / Frailty / Hepatectomy / Humans / Liver Neoplasms / Neoplasm Recurrence, Local / Prognosis (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
15.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : Value of the CRP-albumin ratio in patients with resectable pancreatic cancer., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 244-255, 2021. (Summary) Background : The C-reactive protein (CRP)-albumin ratio (CAR) was reported as a prognostic factor of resectable hepatocellular carcinoma. The aim of this study was to analyse the significance of CAR in resectable pancreatic cancer. Patients and Methods : 163 patients with curative resection for pancreatic cancer were enrolled in this retrospective study. Cases of non-curative resection were excluded. The CAR was calculated with the preoperative plasma CRP and albumin values, with a cut-off value of 0.06, as calculated in a previous report. Results : Patients in the low CAR group had significantly better overall survival (OS) and disease-free survival (DFS) compared with the high CAR group (P < 0.05). On multivariate analysis, for high CAR, CA19-9 > 300 U /l and receipt of adjuvant chemotherapy were independent risk factors for OS and DFS. High CAR was significantly associated with advanced T stage. Conclusion : The CAR might be a prognostic factor for patients with resectable pancreatic cancer. J. Med. Invest. 68 : 244-248, August, 2021. (Keyword) Albumins / C-Reactive Protein / Humans / Pancreatic Neoplasms / Prognosis / Retrospective Studies (Tokushima University Institutional Repository) ● Metadata: 116489 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.244 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759138 ● Search Scopus @ Elsevier (PMID): 34759138 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.244 (Tokushima University Institutional Repository: 116489, DOI: 10.2152/jmi.68.244, PubMed: 34759138)
16.	Shuhai Chen, Tetsuya Ikemoto, Takuya Tokunaga, Shohei Okikawa, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Effective in vitro differentiation of adipose-derived stem cells into Schwann-like cells with folic acid supplementation., The Journal of Medical Investigation : JMI, Vol.68, No.3.4, 347-353, 2021. (Summary) Peripheral nerve injury (PNI) after pelvic surgery is a common issue with a significant impact on patients. Autologous nerve grafting is the gold standard treatment for PNI, but this technique cannot be applied to fine nerve fibers in the pelvis. Schwann-like cell (SLC) differentiation is a novel therapeutic strategy for this clinical condition. However, the efficiency of SLC differentiation remains unsatisfactory. We modified an SLC differentiation protocol using adipose-derived stem cells (ADSCs) and folic acid. Morphology, gene expression and secretion of neurotrophic factors were examined to assess the differentiation quality and phenotypic characteristics. Our new modified protocol effectively induced a Schwann cell (SC) phenotype in ADSCs as assessed by morphology and expression of SC markers [S100 calcium-binding protein B (S100B), P < 0.01 ; p75 neurotrophic receptor (p75NTR), P < 0.05]. SLCs produced by the new protocol displayed a repair phenotype with decreased expression of ERBB2 and early growth response protein 2 (EGR2) /ROX20 (P < 0.01). Furthermore, our new protocol enhanced both mRNA expression and secretion of nerve growth factors by SLCs (P < 0.01). This protocol enhanced the SC characteristics and functions of ADSC-derived SLCs. This promising protocol requires further research and may contribute to SC-based nerve regeneration. J. Med. Invest. 68 : 347-353, August, 2021. (Keyword) Adipose Tissue / Cell Differentiation / Cells, Cultured / Dietary Supplements / Folic Acid / Humans / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116542 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.68.347 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34759157 ● Search Scopus @ Elsevier (PMID): 34759157 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.68.347 (Tokushima University Institutional Repository: 116542, DOI: 10.2152/jmi.68.347, PubMed: 34759157)
17.	Tetsuya Ikemoto, Kazunori Tokuda, Yuuma Wada, Luping Gao, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose Tissue From Type 1 Diabetes Mellitus Patients Can Be Used to Generate Insulin-Producing Cells., Pancreas, Vol.49, No.9, 1225-1231, 2020. (Summary) We aimed to determine whether responsive insulin-producing cells (IPCs) could be generated from adipose-derived stem cells (ADSCs) isolated from patients with type 1 diabetes mellitus (T1DM). We isolated ADSCs from adipose tissue of 4 patients (one patient with T1DM and 3 nondiabetic patients), who underwent surgery and differentiated them into IPCs with using a 2-step xeno-antigen free, 3-dimensional culture method. Characteristics of isolated ADSCs, in vitro cell quality, programmed cell death ligand-1 (PDL-1) expression, and transplantation into streptozotocin induced diabetic nude mice were investigated. Adipose-derived stem cells from T1DM patients and commercially obtained ADSCs showed the same surface markers; CD31CD34CD45CD90CD105CD146. Moreover, the generated IPCs at day 21 demonstrated appropriate autonomous insulin secretion (stimulation index, 3.5; standard deviation, 0.8). Nonfasting blood glucose concentrations of IPC-transplanted mice were normal at 30 days. The normalized rate of IPC-transplanted mice was significantly higher than that of the sham-operated group (P < 0.05). Insulin-producing cells generated from T1DM adipose tissue expressed high levels of PDL-1. Insulin-producing cells obtained from adipose tissue of T1DM patients are capable of secreting insulin long-term and achieve normoglycemia after transplantation. Expression of PDL-1 suggests the potential for immune circumvention. (Link to Publication Site) ● Publication site (DOI): 10.1097/MPA.0000000000001663 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32898009 ● Search Scopus @ Elsevier (PMID): 32898009 ● Search Scopus @ Elsevier (DOI): 10.1097/MPA.0000000000001663 (DOI: 10.1097/MPA.0000000000001663, PubMed: 32898009)
18.	Kazunori Tokuda, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Effectiveness of repeat surgery for recurrence after primary hepatectomy in patients with intrahepatic cholangiocarcinoma., International Journal of Clinical Oncology, Vol.25, No.12, 2083-2089, 2020. (Summary) Intrahepatic cholangiocarcinoma (IHCC) has a poor prognosis, and surgery remains the only effective treatment. However, tumor recurrence after primary hepatectomy is common. We examined the significance of repeat surgery for IHCC. We collected data for all patients with IHCC between 1992 and 2018 (n = 67) in our database. Fifty-three (79.1%) of all 67 patients experienced recurrence after primary hepatectomy and we analyzed data for those 53 recurrent patients. We divided recurrent patients into a repeat surgery group (n = 9), chemotherapy group (n = 19), and best supportive care group (n = 25). We analyzed differences in patients' clinicopathological factors, including prognosis, between the three groups. The IHCC recurrence rate after hepatectomy in our institution was 79.1%. Of the 53 patients with recurrence, nine underwent repeat surgery (17.0%). The characteristics of the patients undergoing repeat surgery was lower stage at primary hepatectomy. Recurrence sites in the repeat surgery group were liver (n = 6), lung (n = 2), and adrenal gland (n = 1), as a single nodule. The period between primary hepatectomy and recurrence was comparatively longer in the repeat surgery group, at 1.8 years. The prognosis in patients undergoing repeat surgery was significantly better compared with the other groups. Not undergoing repeat surgery (hazard ratio: 5.506; p = 0.0077) and positive lymph node metastasis (hazard ratio: 2.207; p = 0.0242) were independent poor prognostic factors. Repeat surgery should be considered in patients with IHCC with a single recurrence site and negative lymph node metastasis at primary surgery and at least more than 6 months of disease-free period after primary surgery. (Keyword) Adrenal Gland Neoplasms / Adrenalectomy / Adult / Aged / Aged, 80 and over / Bile Duct Neoplasms / Bile Ducts, Intrahepatic / Cholangiocarcinoma / Female / Hepatectomy / Humans / Liver Neoplasms / Lung Neoplasms / Lymphatic Metastasis / Male / Middle Aged / Neoplasm Recurrence, Local / Prognosis / Proportional Hazards Models / Reoperation / Treatment Outcome (Link to Publication Site) ● Publication site (DOI): 10.1007/s10147-020-01775-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32869120 ● Search Scopus @ Elsevier (PMID): 32869120 ● Search Scopus @ Elsevier (DOI): 10.1007/s10147-020-01775-x (DOI: 10.1007/s10147-020-01775-x, PubMed: 32869120)
19.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : Impact of using a perioperative artificial endocrine pancreas in pancreatic resection., Annals of Gastroenterological Surgery, Vol.4, No.5, 591-596, 2020. (Summary) Pancreatectomy causes both hyperglycemia, secondary to surgical stress, and pancreatic diabetes, which leads to difficult-to-control postoperative blood glucose levels. We investigated whether using an artificial pancreas perioperatively to provide appropriate blood glucose control could reduce postoperative complications following pancreatectomy. We retrospectively enrolled 52 patients who underwent pancreatectomy at Tokushima University Hospital from 2015 to 2019. The most recent 26/52 patients received perioperative blood glucose control using an artificial pancreas. Postoperative blood glucose control with manual insulin injections based on a sliding scale was performed in the earlier 26 patients (controls). We compared surgical outcomes between the artificial pancreas group and the control group. There was no significant difference in patients' white blood cell or neutrophil counts, prognostic nutritional index, neutrophil-lymphocyte ratio, and C-reactive protein-to-albumin ratio on postoperative day 1; however, lymphocyte counts were higher in the artificial pancreas group. The number of serious complications of Clavien-Dindo grade >IIIa was significantly lower in the artificial pancreas group ( < .05). Using an artificial pancreas for perioperative blood glucose control in patients undergoing pancreatectomy decreased the number of serious complications through proper management of blood glucose levels without hypoglycemia, and may influence peripheral lymphocytes. (Tokushima University Institutional Repository) ● Metadata: 116476 (Link to Publication Site) ● Publication site (DOI): 10.1002/ags3.12374 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33005854 ● Search Scopus @ Elsevier (PMID): 33005854 ● Search Scopus @ Elsevier (DOI): 10.1002/ags3.12374 (Tokushima University Institutional Repository: 116476, DOI: 10.1002/ags3.12374, PubMed: 33005854)
20.	Katsuki Miyazaki, Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : Pancreatoduodenectomy co-morbid with celiac axis compression syndrome: a report of three cases., Surgical Case Reports, Vol.6, No.1, 113, 2020. (Summary) Celiac axis compression syndrome (CACS) is a relatively rare disease. Because of the nature of the blood flow in the celiac region when a pancreatoduodenectomy (PD) is performed for CACS, the celiac region can become ischemic. The aim of this study is to report on the importance of pre-operative diagnosis of CACS in terms of the outcomes for patients post-operatively. In this study, three 3 cases of PD co-morbid with CACS are reported: one intra-operative diagnosis case and two pre-operative diagnosis cases. The one case, not diagnosed with CACS prior to the operation, had a hard post-operative course because of complication caused by ischemia of the celiac region compared with the two cases diagnosed prior to the operation, who had a good post-operative course because of pre-operative or intra-operative intervention. Post-operative complications due to CACS are preventable by pre-operative diagnosis and appropriate interventions. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-020-00878-x (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32449014 ● Search Scopus @ Elsevier (PMID): 32449014 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-020-00878-x (DOI: 10.1186/s40792-020-00878-x, PubMed: 32449014)
21.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Prognostic prediction of apparent diffusion coefficient obtained by diffusion-weighted MRI in mass-forming intrahepatic cholangiocarcinoma., Journal of Hepato-Biliary-Pancreatic Sciences, Vol.27, No.7, 388-395, 2020. (Summary) We evaluated apparent diffusion coefficient (ADC) of diffusion-weighted image MRI as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma (IHCC). We enrolled 26 patients who had undergone hepatic resections for mass-forming-type IHCC in this study, and calculated their mean ADC, using diffusion-weighted image MRI (b: 0, 20, 800 seconds/mm ; 1.5 T MRI). Patients were divided into the ADC and the ADC groups at the median ADC value (n = 13 for both). We also immunohistochemically evaluated hypoxia-inducible factor (HIF)-1 in tumor tissue. Median age in the ADC was older (P = .03), and showed significant higher rate of scirrhous tumor (P = .02). The 5-year overall survival rate in the ADC group was significantly worse than in the ADC group (P = .04). In multivariate analysis, hilar tumor, portal vein invasion and low ADC were independent prognostic factors (P < .05). The ADC group also had a higher rate of high HIF-1 expression than the ADC group (P < .05). Representative case of ADC group showed rich stroma and high HIF-1 expression. The ADC values in MRIs can predict IHCC prognosis, and correlated with stromal density and HIF-1 expression. (Keyword) Aged / Algorithms / Bile Duct Neoplasms / Biomarkers, Tumor / Cholangiocarcinoma / Contrast Media / Diffusion Magnetic Resonance Imaging / Female / Hepatectomy / Humans / Hypoxia-Inducible Factor 1, alpha Subunit / Male / Neoplasm Invasiveness / Prognosis / Survival Rate / Tomography, X-Ray Computed (Link to Publication Site) ● Publication site (DOI): 10.1002/jhbp.732 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32162483 ● Search Scopus @ Elsevier (PMID): 32162483 ● Search Scopus @ Elsevier (DOI): 10.1002/jhbp.732 (DOI: 10.1002/jhbp.732, PubMed: 32162483)
22.	Kazunori Tokuda, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shoko Yamashita, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : The Fragility of Cryopreserved Insulin-producing Cells Differentiated from Adipose-tissue-derived Stem Cells., Cell Transplantation, Vol.29, 963689720954798, 2020. (Summary) The aim of our study is to determine whether insulin-producing cells (IPCs) differentiated from adipose-tissue-derived stem cells (ADSCs) can be cryopreserved. Human ADSCs were differentiated into IPCs using our two-step protocol encompassing a three-dimensional culture and xenoantigen-free method. Thereafter, IPCs were frozen using three different methods. First, IPCs were immediately frozen at -80 C (-80 C group). Second, IPCs were initially placed into a Bicell freezing container before freezing at -80 C (BICELL group). Third, a vitrification method for oocytes and embryos was used (CRYOTOP group). Cell counting kit-8 (CCK-8) assay showed that cell viability was decreased in all groups after cryopreservation ( < 0.01). Corroboratively, the amount of adenosine triphosphate was markedly decreased after cryopreservation in all groups ( < 0.01). Immunofluorescence staining showed a reduced positive staining area for insulin in all cryopreservation groups. Furthermore, 4',6-diamidino-2-phenylindole and merged immunofluorescence images showed that cryopreserved cells appeared to be randomly reduced in the -80 C group and CRYOTOP group, while only the central region was visibly reduced in the BICELL group. Using immunohistochemical staining, IPCs after cryopreservation were shown to be positive for cleaved caspase-3 antibody in all groups. Finally, insulin secretion following glucose stimulation was significantly reduced in IPCs from all groups after cryopreservation ( < 0.01). In conclusion, IPCs may be too fragile for cryopreservation with accomplished methods and further investigations for a suitable preservation method are required. (Keyword) Adenosine Triphosphate / Adipose Tissue / Caspase 3 / Cell Differentiation / Cell Shape / Cell Survival / Cryopreservation / Dithizone / Glucose / Humans / Insulin / Insulin Secretion / Insulin-Secreting Cells / Staining and Labeling / Stem Cells (Tokushima University Institutional Repository) ● Metadata: 116513 (Link to Publication Site) ● Publication site (DOI): 10.1177/0963689720954798 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32878465 ● Search Scopus @ Elsevier (PMID): 32878465 ● Search Scopus @ Elsevier (DOI): 10.1177/0963689720954798 (Tokushima University Institutional Repository: 116513, DOI: 10.1177/0963689720954798, PubMed: 32878465)

Proceeding of International Conference:

1.	Kazunori Tokuda, Mitsuo Shimada, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The investigation of optimal transplantation site of insulin producing cell differentiated from human adipose derived stem cell., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.194 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.194 (DOI: 10.1016/j.jcyt.2020.03.194)
2.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Satoru Imura and Yuji Morine : The generation of effective insulin-producing cells from ADSC derived from type 1 diabetes mellitus patients., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.147 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.147 (DOI: 10.1016/j.jcyt.2020.03.147)
3.	Mitsuo Shimada, Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Yusuke Arakawa, Satoru Imura and Yuji Morine : Long-term results of transplanted insulin producing cells differented from human adipose stem cells in mice., ISCT2020, Paris, May 2020. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jcyt.2020.03.186 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1016/j.jcyt.2020.03.186 (DOI: 10.1016/j.jcyt.2020.03.186)
4.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty in prognosis after hepatectomy in older patients with hepatocellular carcinoma., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1245/s10434-020-08742-w (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32562115 ● Search Scopus @ Elsevier (PMID): 32562115 ● Search Scopus @ Elsevier (DOI): 10.1245/s10434-020-08742-w (DOI: 10.1245/s10434-020-08742-w, PubMed: 32562115)
5.	Yusuke Arakawa, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Evaluation of the ratio of plasma fibrinogen to platelet in resectable pancreatic cancer., ASCO-GI, San Francisco, Jan. 2020. (Link to Publication Site) ● Publication site (DOI): 10.1200/JCO.2020.38.4_suppl.756 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.1200/JCO.2020.38.4_suppl.756 (DOI: 10.1200/JCO.2020.38.4_suppl.756)
6.	Masato Yoshikawa, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, IASGO2019, Bangkok, Oct. 2019.
7.	Katsuki Miyazaki, Tetsuya Ikemoto, Mitsuo Shimada, Feng Rui, Yu Saitou, Shuichi Iwahashi, Yuji Morine and Satoru Imura : THE IMPACT OF RED LED IRRADIATION ON DIFFERENTIATION FOR INSULIN-PRODUCING CELLS FROM MESENCHYMAL STEM CELL, ESOT2019, Copenhagen, Sep. 2019.

Proceeding of Domestic Conference:

1.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : 肉眼的門脈浸潤を伴う進行肝細胞癌の治療戦略, 第78回日本消化器外科学会総会, Jul. 2023.
2.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Yuhei Waki, Tetsuya Ikemoto and Mitsuo Shimada : Reconsideration of indication of hepatic for advanced hepatocellular carcinoma and significance of conversion surgery, 第35回日本肝胆膵外科学会学術集会, Jun. 2023.
3.	Chie Takasu, Gao Luping, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : Nrf2を介した微小環境クロストークによる肝細胞癌薬剤耐性機序解明に関する研究, 第32回日本消化器癌発生学会総会, Nov. 2021.
4.	Shohei Okikawa, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, NAKASU Chiharu and Mitsuo Shimada : VEGF阻害はTAMの悪性度を減じる, 第32回日本消化器癌発生学会総会, Nov. 2021.
5.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第32回日本消化器癌発生学会総会, Nov. 2021.
6.	Yu Saitou, 杉本真樹, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : Extended reality(VR・AR・MR)を駆使した手術ナビゲーション, 第83回日本臨床外科学会総会, Nov. 2021.
7.	Yu Saitou, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 地方から世界に通用する一流の外科医を目指した取り組み, 第83回日本臨床外科学会総会, Nov. 2021.
8.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto and Mitsuo Shimada : 進行肝細胞癌に対する外科切除成績とConversion surgeryの意義, 第83回日本臨床外科学会総会, Nov. 2021.
9.	Shohei Okikawa, Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第57回日本胆道学会学術集会, Oct. 2021.
10.	Shin-ichiro Yamada, Katsuki Miyazaki, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第57回日本胆道学会学術集会, Oct. 2021.
11.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : The role of BAFF/BAFF receptor in microenvironment of sorafenib resistant he patocellular carcinoma, 第80回日本癌学会学術総会, Sep. 2021.
12.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : 生体肝移植術後短期長期成績に関する検討, 第57回日本移植学会総会, Sep. 2021.
13.	Hiroki Teraoku, Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞を基にした機能的肝細胞様細胞の分化誘導, 第57回日本移植学会総会, Sep. 2021.
14.	Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Shohei Okikawa, Hiroki Teraoku, Shin-ichiro Yamada, Yuji Morine and Mitsuo Shimada : 再生医療を用いたインスリン産生細胞自家移植による1型糖尿病根治治療確立へ向けた戦略, 第57回日本移植学会総会, Sep. 2021.
15.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出-肝不全・代謝性肝疾患に対する肝移植から細胞治療へ-, 第263回徳島医学会学術集会(令和3年度夏期), Aug. 2021.
16.	Shin-ichiro Yamada, Gao Luping, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Shohei Okikawa, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : ソラフェニブ耐性肝細胞癌の腫瘍微小環境形成におけるBAFF/BAFF受容体の役割, 第57回日本肝癌研究会, Jul. 2021.
17.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第57回日本肝癌研究会, Jul. 2021.
18.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第57回日本肝癌研究会, Jul. 2021.
19.	TAKAHASHI Akira, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Katsuki Miyazaki and Mitsuo Shimada : DWI-MRIによる進行胆嚢癌の腫瘍悪性度評価, 第76回日本消化器外科学会総, Jul. 2021.
20.	NAKASU Chiharu, Tetsuya Ikemoto, Takuya Tokunaga, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からSchwann-like cellの効果的分化誘導方法の研究, 第76回日本消化器外科学会総会, Jul. 2021.
21.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としての腫瘍浸潤リンパ球の意義, 第76回日本消化器外科学会総会, Jul. 2021.
22.	Kazunori Tokuda, Yuji Morine, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝細胞癌の腫瘍微小環境におけるOsteopontinを介したCAF-TAM interactionについての検討, 第76回日本消化器外科学会総会, Jul. 2021.
23.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第76回日本消化器外科学会総会, Jul. 2021.
24.	Yu Saitou, Maki Sugimoto, Yuji Morine, Tetsuya Ikemoto, Takuya Tokunaga, Hiroki Teraoku, Katsuki Miyazaki, Takashi Iwata and Mitsuo Shimada : Navigation of rectal and hepatobiliary pancreatic surgery with intraoperative hologram, 第76回日本消化器外科学会総会, Jul. 2021.
25.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Hiroki Teraoku, Shohei Okikawa, Shin-ichiro Yamada, Satoru Imura and Yuji Morine : 消化器外科領域の幹細胞トランスレーショナルリサーチにおける医工連携, 第76回日本消化器外科学会総会, Jul. 2021.
26.	Hiroki Teraoku, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Yu Saitou, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 両葉多発大腸癌肝転移に対する肝切除適応基準とConversion Surgery, 第76回日本消化器外科学会総会, Jul. 2021.
27.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 進行肝細胞癌集学的治療における外科切除の役割:Conversion Surgery成績も含めて, 第76回日本消化器外科学会総会, Jul. 2021.
28.	Shin-ichiro Yamada, Yuji Morine, Tetsuya Ikemoto, Yu Saitou, Hiroki Teraoku, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : 高齢者に対する肝胆膵手術におけるFrailtyの意義に関する検討, 第115回日本消化器病学会四国支部例会, Jun. 2021.
29.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Tetsuya Ikemoto, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 小胞体ストレス応答に着目した非アルコール性脂肪肝炎の肝切除後肝再生/肝不全に関する研究, 第47回日本急性肝不全研究会, Jun. 2021.
30.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Koichi Tsuneyama and Mitsuo Shimada : Endoplasmic reticulum stress response deficiency is a major cause of poor liver regeneration after hepatectomy in nonalcoholic steatohepatitis, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
31.	Hiroki Teraoku, Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou and Katsuki Miyazaki : Significance of frailty for eldery patients in HPB surgery, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
32.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Hiroki Teraoku, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Treatment strategy of multiple colorectal liver metastasis-Criteria for upfront surgery and Conversion Surgery-, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
33.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Hiroki Teraoku and Katsuki Miyazaki : Clinical application of auto-transplantation of generated insulin-producing cells from ADSC with Tokushima protocol, 第33回日本肝胆膵外科学会学術集会, Jun. 2021.
34.	Katsuki Miyazaki, Yu Saitou, Mayuko Shimizu, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Koichi Tsuneyama and Mitsuo Shimada : 非アルコール性脂肪性肝疾患(NAFLD)における肝切除後肝再生機能不全に関する研究- 小胞体ストレス応答不全の観点より -, 第 121 回日本外科学会定期学術集会, Apr. 2021.
35.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 肝門部領域胆管癌の切除成績と術後補助療法の意義, 第121回日本外科学会定期学術集会, Apr. 2021.
36.	TAKAHASHI Akira, Yu Saitou, Tetsuya Ikemoto, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞ADSCからのSuper HLC (肝細胞様細胞)の創出, 第121回日本外科学会定期学術集会, Apr. 2021.
37.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : Adipose derived stem cellから作製したInsulin producing cellの臨床応用に向けた保存方法に関する研究, 第121回日本外科学会定期学術集会, Apr. 2021.
38.	Hiroki Teraoku, Gao Luping, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第121回日本外科学会定期学術集会, Apr. 2021.
39.	Shohei Okikawa, Yuji Morine, Kazunori Tokuda, Yu Saitou, Shin-ichiro Yamada, Shoko Yamashita, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 腫瘍微小環境におけるOsteopontinの意義, 第121回日本外科学会定期学術集会, Apr. 2021.
40.	Shin-ichiro Yamada, 陳術海, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌微小環境におけるPAI-1発現の意義に関する検討, Apr. 2021.
41.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Katsuki Miyazaki, Shin-ichiro Yamada, Yu Saitou, Satoru Imura and Yuji Morine : 再生医療を用いたインスリン枯渇状態の患者に対する自律的インスリン分泌細胞自己移植に関するAMED橋渡し研究, 第121回日本外科学会定期学術集会, Apr. 2021.
42.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shoko Yamashita, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から作製したインスリン産生細胞の至適保存方法に関する研究, 第20回日本再生医療学会総会, Mar. 2021.
43.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出, 第20回日本再生医療学会総会, Mar. 2021.
44.	Yuji Morine, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Katsuki Miyazaki, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 徳島大学の肝胆膵外科における若手教育-特に内視鏡手術に焦点をあてて-, 第33回日本内視鏡外科学会, Mar. 2021.
45.	Yu Saitou, Tetsuya Ikemoto, Katsuki Miyazaki, Kazunori Tokuda, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から肝細胞様細胞の創出- 肝不全・代謝性肝疾患に対する肝移植から細胞治療へ -, 第262回徳島医学会学術集会, Mar. 2021.
46.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Significance of frailty for elderly patients in HPB surgery, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
47.	Yu Saitou, Tetsuya Ikemoto, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Maki Sugimoto and Mitsuo Shimada : Intraoperative support with 3D holographic cholangiography and indocyanine green navigation, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
48.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : The impact of frailty as a prognostic factor of colorectal liver metastasis, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
49.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : The value of CRP albumin ratio in patient with resectable pancreas cancer, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
50.	Tetsuya Ikemoto, Kazunori Tokuda, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Basic research for aiming non-clinical PoC acquisition of insulin producing cells from ADSC with Tokushima protocol, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
51.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : Optimal surgical treatment including lymph nodes dissection and adjuvant chemotherapy for intrahepatic cholangiocarcinoma, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
52.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : Standardization and stepwise training for safe laparoscopic hepatectomy, 第32回日本肝胆膵外科学会学術集会, Feb. 2021.
53.	Shin-ichiro Yamada, 高露泙, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita and Katsuki Miyazaki : 肝細胞癌におけるSorafenib耐性獲得機序に関する検討, 第23回日本肝がん分子標的治療研究会, Jan. 2021.
54.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Kazunori Tokuda and Katsuki Miyazaki : 肝胆膵領域悪性腫瘍におけるNrf2・VEGFに着目した腫瘍関連マクロファージ活性化についての検討, 第29回日本癌病態治療研究, Jan. 2021.
55.	Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第38回日本肝移植学会学術集, Dec. 2020.
56.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた術中手術支援-術中Real-time3D胆管造影を併用した胆道手術-, 第45回日本外科系連合学会学術集会, Dec. 2020.
57.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第56回日本肝癌研究会, Dec. 2020.
58.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第56回日本肝癌研究会, Dec. 2020.
59.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第56回日本肝癌研究会, Dec. 2020.
60.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou and Shin-ichiro Yamada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第75回日本消化器外科学会総会, Dec. 2020.
61.	Toshiaki Yoshimoto, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, Yukako Takehara and Mitsuo Shimada : 膵切除周術期における栄養指標からみた人工膵臓の有用性, 第75回日本消化器外科学会総会, Dec. 2020.
62.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の切除後予後予測，抗癌剤効果予測に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
63.	Kazunori Tokuda, Yuji Morine, Shin-ichiro Yamada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 転移性肝癌切除症例におけるFrailの重要性についての検討, 第75回日本消化器外科学会総会, Dec. 2020.
64.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 胆嚢癌の悪性度評価におけるADCの有用性に関する検討, 第75回日本消化器外科学会総会, Dec. 2020.
65.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第75回日本消化器外科学会総会, Dec. 2020.
66.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 当院の肝胆膵手術症例におけるSSIサーベイランスによる検討, 第75回日本消化器外科学会総会, Dec. 2020.
67.	Tetsuya Ikemoto, Mitsuo Shimada, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 長期予後と患者QoLに着目した膵全摘症例の検討, 第75回日本消化器外科学会総会, Dec. 2020.
68.	Yuji Morine, Mitsuo Shimada, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : 大腸癌同時性肝転移に対する治療戦略-肝切除適応基準とConversion Surgery-, 第75回日本消化器外科学会総会, Dec. 2020.
69.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 腹腔鏡下肝左葉切除の標準化への取り組み ∼手技定型化とstepwise training∼, 第75回日本消化器外科学会総会, Dec. 2020.
70.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Takeshi Oya, Koichi Tsuneyama and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのリンパ球CRP比の意義と腫瘍浸潤リンパ球との関係, 第31回日本消化器癌発生学会総会, Nov. 2020.
71.	Shin-ichiro Yamada, 高露萍, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : ソラフェニブ耐性肝癌において，Nrf2は幹細胞性・遊走能・ABCトランスポーター発現を促進する, 第31回日本消化器癌発生学会総会, Nov. 2020.
72.	Katsuki Miyazaki, Yu Saitou, 高露萍, Tetsuya Ikemoto, Shin-ichiro Yamada, Satoru Imura, Yuji Morine, Masato Miyake, Seiichi Oyadomari and Mitsuo Shimada : ヒト脂肪由来間葉系幹細胞から分化誘導した肝細胞様細胞の遺伝子発現解析, 第56回日本移植学会総会, Nov. 2020.
73.	Kazunori Tokuda, Tetsuya Ikemoto, Katsuki Miyazaki, Shohei Okikawa, Shin-ichiro Yamada, Yu Saitou, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞から分化誘導したインスリン産生細胞の凍結保存方法についての検討, 第56回日本移植学会総会, Nov. 2020.
74.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 移植医から提案する再生医療技術を用いたインスリン産生細胞自家移植による1型糖尿病根治へ向けた戦略, 第56回日本移植学会総会, Nov. 2020.
75.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Shin-ichiro Yamada, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 医療系学生に対するDonor Action(命の授業)の必要性, 第56回日本移植学会総会, Oct. 2020.
76.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例における，Frailtyの意義に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
77.	Tetsuya Ikemoto, Kazunori Tokuda, Yu Saitou, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 再生医療技術による1型糖尿病根治へ向けたシーズの臨床応用に関する検討, 第82回日本臨床外科学会総会, Oct. 2020.
78.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Kazunori Tokuda, Shohei Okikawa, Shoko Yamashita, Katsuki Miyazaki and Mitsuo Shimada : Microbiome, HSCに着目した大建中湯の消化器癌に対する多面的効果の検討, 第82回日本臨床外科学会総会, Oct. 2020.
79.	Katsuki Miyazaki, Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 膵頭十二指腸切除術(PD)術後合併症回避に向けた腹腔動脈起始部圧迫症候群の周術期管理, 第56回日本腹部救急医学会総会, Oct. 2020.
80.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Katsuki Miyazaki, Mitsuo Shimada and 高露泙 : ソラフェニブ耐性肝細胞癌において，Nrf2は肝細胞性，遊走能，ABC transporterの発現を上昇させる, --- Nrf2 signaling promotes cancer stemness, migration and expression of ABC transporters in sorafenib-resistant HCC ---, 第79回日本癌学会学術集会, Oct. 2020.
81.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第120回日本外科学会定期学術集会, Aug. 2020.
82.	Masato Yoshikawa, Yuji Morine, Shin-ichiro Yamada, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : DWI-MRIのADC値を用いた転移性肝癌の予後予測に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
83.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 膵癌術後予後予測因子としての術前fibrinogen:血小板比の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
84.	Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 切除可能大腸癌限局性肝転移の治療指針, 第120回日本外科学会定期学術集会, Aug. 2020.
85.	Kazunori Tokuda, Tetsuya Ikemoto, 高露萍, Yuji Morine, Satoru Imura, Yu Saitou, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 肪由来幹細胞(ADSC)から肝細胞様細胞(HLC)への分化誘導における3D培養の有用性, 第120回日本外科学会定期学術集会, Aug. 2020.
86.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : 膵癌切除症例におけるFrailの意義に関する検討, 第120回日本外科学会定期学術集会, Aug. 2020.
87.	Yu Saitou, Mitsuo Shimada, 杉本真樹, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa and Katsuki Miyazaki : Holographyを用いた次世代術中手術支援とICG蛍光法による肝離断navigation, 第120回日本外科学会定期学術集会, Aug. 2020.
88.	Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Kazunori Tokuda, Shin-ichiro Yamada, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 小型肝癌に対する肝実質温存肝区画切除は妥当である, 第120回日本外科学会定期学術集会, Aug. 2020.
89.	Katsuki Miyazaki, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte/CRP ratio(LCR)の意義, 第113回日本消化器病学会四国支部例会, Jun. 2020.
90.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Shin-ichiro Yamada, Katsuki Miyazaki and Mitsuo Shimada : DAA治療後SVR症例は発癌Potentialが高く進行病期に関与する, 第113回日本消化器病学会四国支部例会, Jun. 2020.
91.	Yu Saitou, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への3次元分化誘導, 第19回日本再生医療学会総会, May 2020.
92.	Tetsuya Ikemoto, Mitsuo Shimada, Kazunori Tokuda, Yu Saitou, Masato Yoshikawa, Katsuki Miyazaki, Shin-ichiro Yamada, Yusuke Arakawa, Satoru Imura and Yuji Morine : T1DM患者から採取された脂肪組織から分離したADSCから製造したInsulin-producing cellに関する検討, 第19回日本再生医療学会総会, May 2020.
93.	Katsuki Miyazaki, Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Kazunori Tokuda, Masato Yoshikawa and Mitsuo Shimada : 肝内胆管癌予後規定因子としてのLymphocyte / CRP ratio (LCR)の意義, 第53回制癌剤適応研究会, Feb. 2020.
94.	Masato Yoshikawa, Shin-ichiro Yamada, Yuji Morine, Katsuki Miyazaki, Kazunori Tokuda, Yu Saitou, Yusuke Arakawa, Tetsuya Ikemoto, Satoru Imura and Mitsuo Shimada : 転移性肝癌におけるDWI-MRIのADC値を用いた予後予測に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
95.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 腫瘍関連マクロファージを介した肝胆膵癌の悪性度獲得に関する検討, 第53回制癌剤適応研究会, Feb. 2020.
96.	Yu Saitou, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki and Mitsuo Shimada : NBNC肝細胞癌の発癌と進展の分子標的からみた治療戦略, 第53回制癌剤適応研究会, Feb. 2020.
97.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第81回日本臨床外科学会総会, Nov. 2019.
98.	Takuya Tokunaga, Mitsuo Shimada, Kouzou Yoshikawa, Tomohiko Miyatani, Masaaki Nishi, Hideya Kashihara, Chie Takasu, Toshiaki Yoshimoto, Yukako Takehara and Katsuki Miyazaki : 下部直腸癌に対する経肛門的アプローチ(TaTME)∼術中尿道造影の有用性∼, 第112回日本消化器病学会四国支部例会, Nov. 2019.
99.	Shin-ichiro Yamada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa, Toshiaki Yoshimoto, Katsuki Miyazaki and Mitsuo Shimada : 肝細胞癌に対する肝切除術におけるFrailtyの意義に関する検討, 第57回日本癌治療学会学術集会, Oct. 2019.
100.	Masato Yoshikawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Yusuke Arakawa, Katsuki Miyazaki, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第55回日本移植学会総会, Oct. 2019.
101.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性 –, 第55回日本移植学会総会, Oct. 2019.
102.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Satoru Imura, Yuji Morine and Mitsuo Shimada : 脂肪由来幹細胞からインスリン産生細胞への分化誘導における赤色LEDの有用性に関する研究, 第55回日本移植学会総会, Oct. 2019.
103.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : Prognostic prediction of mass-forming intrahepatic cholangiocarcinoma from ADC value of DWI-MRI, JSH International Liver Conference, Oct. 2019.
104.	Yusuke Arakawa, Katsuki Miyazaki, Masato Yoshikawa, Shin-ichiro Yamada, Yu Saitou, Tetsuya Ikemoto, Satoru Imura, Yuji Morine and Mitsuo Shimada : 肝癌細胞におけるNrf2に着目した腫瘍関連マクロファージ活性化の検討, 第78回日本癌学会学術総会, Sep. 2019.
105.	Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Yusuke Arakawa, Shin-ichiro Yamada, Masato Yoshikawa, Katsuki Miyazaki, 杉本真樹 and Mitsuo Shimada : Hologramを用いた次世代術前術中手術支援とICG蛍光法による肝離断navigation, 第14回肝癌治療ナビゲーション研究会, Sep. 2019.
106.	Masato Yoshikawa, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Yusuke Arakawa, Yu Saitou, Shin-ichiro Yamada, Katsuki Miyazaki, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の二例, 第71回日本消化器画像診断研究会, Sep. 2019.
107.	Shin-ichiro Yamada, Mitsuo Shimada, Yuji Morine, Satoru Imura, Tetsuya Ikemoto, Yusuke Arakawa, Yu Saitou, Masato Yoshikawa and Katsuki Miyazaki : MRI拡散強調画像から見た肝内胆管癌の腫瘍悪性度に関する検討, 第71回日本消化器画像診断研究会, Sep. 2019.
108.	Yu Saitou, Satoru Imura, Katsuki Miyazaki, Masato Yoshikawa, Yusuke Arakawa, Tetsuya Ikemoto, Yuji Morine and Mitsuo Shimada : 脳死肝移植ドナー不足解消にむけての取り組み- 医療系学生に対するDonor Action(命の授業)の必要性-, 第37回日本肝移植学会, Jul. 2019.
109.	Yusuke Arakawa, Yu Saitou, 高露萍, Tetsuya Ikemoto, Katsuki Miyazaki, Masato Yoshikawa, Satoru Imura, Yuji Morine and Mitsuo Shimada : GSK3 inhibitorsを用いた脂肪由来間葉系幹細胞から肝細胞様細胞への分化誘導, 第37回日本肝移植学会, Jul. 2019.
110.	Katsuki Miyazaki : 腹腔動脈起始部圧迫症候群を合併した膵頭十二指腸切除2症例, 第74回日本消化器外科学会総会, Jul. 2019.
111.	Katsuki Miyazaki, Yu Saitou, Satoru Imura, Yuji Morine, Tetsuya Ikemoto, Shuichi Iwahashi, Shin-ichiro Yamada and Mitsuo Shimada : A case of preoperative nutritional and exercise intervention in HCC patient with alcoholic liver cirrhosis, 第31回日本肝胆膵外科学会学術集会, Jun. 2019.
112.	Katsuki Miyazaki, Shoko Iwahashi, Tetsuya Ikemoto, Yuji Morine, Satoru Imura, Shuichi Iwahashi, Yu Saitou, Shin-ichiro Yamada, Koichi Tsuneyama and Mitsuo Shimada : 卵巣様間質を伴う非粘液性嚢胞腺腫の2例, 第119回日本外科学会定期学術集会, Apr. 2019.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

Hyperprogressive disease(HPD)における腫瘍関連マクロファージの意義の解明 (Project/Area Number: 24K23491 )
Search by Researcher Number (30846126)

Designated Assistant Professor : Miyazaki, Katsuki

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Academic Paper (Unrefereed Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)